Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

NCT07347418 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT07347418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07347418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2026
Completion date
June 30, 2032
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myeloid leukemia), myelodysplastic syndrome, refractory acute myeloid leukemia (aml), relapsed acute myeloid leukemia (aml)